Recent coverage of innovative research and development across the biopharma and medtech sectors.
READ NOWFeatured Stories
How Sanofi Is Embracing AI In Everyday Operations
Senior management at the Paris-headquartered drugmaker tell In Vivo about how embracing artificial intelligence has enhanced its ability to accelerate drug discovery, improve clinical trial design and revolutionize its manufacturing and supply processes.
Kiji Takes Flight With Off-The-Shelf Stem Cells
Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.
Podcast: The Colorful Landscape Of Therapeutic Psychedelics
Datamonitor Healthcare analysts and podcast co-hosts Flora Mackay and Emma Wille discuss the complicated development of therapeutic psychedelics. They dwell on FDA involvement and advisory committees, alongside adverse event reporting and ethical concerns.
Latest Articles
2025’s Therapy Area Growth Drivers And Brakes: Part Three
The final instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on mood disorders, immunodeficiency, viral infections, and blood cell disorders.
US Approvals Of Novel Drugs Set To Hit 10-Year High In 2025
But 2024 will see a lull between two strong years.
Biopharma’s Fastest Growing Technology Groups
The next six years will see rapid growth in several newer pharmaceutical technology groups. In this article In Vivo examines the technologies currently forecast to see highest rates of growth, as well as those with the most actual sales growth out to 2030.
Balancing Up The Clinician Burnout-AI Equation
The medical industry must scale up to meet rising demand for care with fewer clinicians. Artificial intelligence can take care to the next levels of volume and quality – and in equity of delivery, insists the company, Annalise.ai.
Kiji Takes Flight With Off-The-Shelf Stem Cells
Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.
Podcast: The Colorful Landscape Of Therapeutic Psychedelics
Datamonitor Healthcare analysts and podcast co-hosts Flora Mackay and Emma Wille discuss the complicated development of therapeutic psychedelics. They dwell on FDA involvement and advisory committees, alongside adverse event reporting and ethical concerns.
How Sanofi Is Embracing AI In Everyday Operations
Senior management at the Paris-headquartered drugmaker tell In Vivo about how embracing artificial intelligence has enhanced its ability to accelerate drug discovery, improve clinical trial design and revolutionize its manufacturing and supply processes.
Biophotonics Sheds A New Light On Diagnostics
Photonics enhances diagnostic imaging accuracy and speeds up diagnoses, says Antanus Laurutis, CEO of Altechna.
Kiji Takes Flight With Off-The-Shelf Stem Cells
Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.
AstraZeneca Believes Size Matters In Amyloidosis
Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.
Execs On The Move: August 2024
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
'Not Going With The Crowd’: Mapping Gene Potential With ProFound Therapeutics
John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.
US Generics Players Enjoy Calmer Waters
After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape.
Market Prices Or Political Expediency? Amgen’s US Lawsuit Seen As Litmus Test
As the US struggles to contain the cost of prescription medicines, a growing number of state governments are trying to take matters into their own hands and believe prescription drug affordability boards could be the answer.
The Future Of Medical Evidence Generation
Boston Consulting Group and senior pharma industry executives take a broad look at the challenges and opportunities for medical affairs evidence generation with multiple modalities.
Market Access Strategies: Nudging Negotiations Along
Deals in pharma to secure market access are now business as usual. More deals will be needed in future too. Yet they take time and are not easy to successfully conclude. Could nudging the negotiations help?
Podcast: The Colorful Landscape Of Therapeutic Psychedelics
Datamonitor Healthcare analysts and podcast co-hosts Flora Mackay and Emma Wille discuss the complicated development of therapeutic psychedelics. They dwell on FDA involvement and advisory committees, alongside adverse event reporting and ethical concerns.
Deals Shaping The Industry, August 2024
An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.
US Generics Players Enjoy Calmer Waters
After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape.
Deals in Depth: August 2024
Six $1bn+ alliances were penned in August. In the top alliance by deal value, ImmuneOnco Biopharmaceuticals licensed Instil Bio global rights (excluding China, Taiwan, Macau, and Hong Kong) to develop and commercialize its PD-L1xVEGF bispecific antibody IMM2510 and the next-generation anti-CTLA-4 antibody IMM27M. The deal could be worth over $2bn. The candidates have potential in treating advanced solid tumors.
AstraZeneca Believes Size Matters In Amyloidosis
Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.
Deals Shaping The Industry, August 2024
An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.
US Generics Players Enjoy Calmer Waters
After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape.
Final Chance To Have Your Say: Take Our Reader Survey This Week
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
How Sanofi Is Embracing AI In Everyday Operations
Senior management at the Paris-headquartered drugmaker tell In Vivo about how embracing artificial intelligence has enhanced its ability to accelerate drug discovery, improve clinical trial design and revolutionize its manufacturing and supply processes.
Biophotonics Sheds A New Light On Diagnostics
Photonics enhances diagnostic imaging accuracy and speeds up diagnoses, says Antanus Laurutis, CEO of Altechna.
First Stage Of UK NHS Review 2024: Darzi Delivers His Early Verdict
Can the new UK government's raw enthusiasm for NHS reform be a catalyst for real change where countless past attempts to address the national provider's shortcomings have failed to hit the spot? And what might the 10-year plan mean for medtech?
Deals in Depth: August 2024
Six $1bn+ alliances were penned in August. In the top alliance by deal value, ImmuneOnco Biopharmaceuticals licensed Instil Bio global rights (excluding China, Taiwan, Macau, and Hong Kong) to develop and commercialize its PD-L1xVEGF bispecific antibody IMM2510 and the next-generation anti-CTLA-4 antibody IMM27M. The deal could be worth over $2bn. The candidates have potential in treating advanced solid tumors.
2025’s Therapy Area Growth Drivers And Brakes: Part Three
The final instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on mood disorders, immunodeficiency, viral infections, and blood cell disorders.
US Approvals Of Novel Drugs Set To Hit 10-Year High In 2025
But 2024 will see a lull between two strong years.
Focus On Cardio-Oncology, Clinical Trends And AI At ESC 2024
Updated guidance on the risk of cardiotoxicity in patients following cancer treatment is expected soon. The first consensus guidelines were issued eight years ago. AI is being used for early risk identification, Philips said during the European Society of Cardiology congress 2024.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.